A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statins

For the first time in India, Zydus Lifesciences Ltd. (formerly Cadila Healthcare Ltd) has launched a new class of drug 'Bemdac' to treat uncontrolled low density lipoprotein cholesterol (LDL-c).

With uncontrolled LDL-c posing a major risk of developing cardiovascular diseases, the same was lacking proper treatment despite patients' life-style modifications and use of maximum tolerated dose of statins. However, now addressing the pressing healthcare need, the oral drug Bemdac will offer a new line of treatment for patients from uncontrolled levels of LDL-c.

Often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels,